Objective-Susceptibility to atherosclerosis is genetically complex, and modifier genes that do not operate via traditional risk factors are largely unknown. A mouse genetics approach can simplify the genetic analysis and provide tools for mechanistic studies. Methods and Results-We previously identified atherosclerosis susceptibility QTL (Athsq1) on chromosome 4 acting independently of systemic risk factors. We now report confirmation of this locus in congenic strains carrying the MOLF-derived susceptibility allele in the C57BL/6J-Ldlr Ϫ/Ϫ genetic background. Homozygous congenic mice exhibited up to 4.5-fold greater lesion area compared to noncongenic littermates (PϽ0.0001). Analysis of extracellular matrix composition revealed prominent accumulation of versican, a presumed proatherogenic matrix component abundant in human lesions but almost absent in the widely-used C57BL/6 murine atherosclerosis model. The results of a bone marrow transplantation experiment suggested that both accelerated lesion development and versican accumulation are mediated, at least in part, by macrophages. Interestingly, comparative mapping revealed that the Athsq1 congenic interval contains the mouse region homologous to a widely-replicated CHD locus on human chromosome 9p21. Conclusion-These studies confirm the proatherogenic activity of a novel gene(s) in the MOLF-derived Athsq1 locus and provide in vivo evidence for a causative role of versican in lesion development. (Arterioscler Thromb Vasc Biol. 2008;28:2180-2186.)
S usceptibility to atherosclerosis is influenced by both genetic and environmental factors, with approximately 40% to 60% of interindividual variation attributed to genetic factors. 1 The complex etiology has hampered genetic studies of atherosclerosis in humans per se until recently. Early studies used the candidate gene approach to identify rare genetic variants contributing to traditional risk factors including plasma levels of LDL/VLDL, HDL, lipoprotein (a), homocysteine, and blood pressure. [2] [3] [4] [5] [6] Now many of the genes underlying Mendelian forms of dyslipidemia have been shown to contribute to population variation of plasma lipids using genome-wide association (GWA) studies. [7] [8] [9] Attempts to identify genes directly underlying coronary artery disease (CAD)/ myocardial infarct (MI) were first pursued through linkage studies of families enriched for disease 10 -14 and large-scale association studies. [15] [16] [17] [18] However, the first locus to be widely-replicated for CHD was recently revealed through a series of GWA studies. 19 -22 A common variant was localized to chromosome (chr) 9p21, but the underlying gene and mechanism of action are unknown. Thus, while a number of genes contributing to traditional risk factors have been identified, few of the genes underlying nontraditional risk factors are known.
Animal models offer an alternative approach for the genetic analysis of complex diseases such as atherosclerosis. In early work, the existence of atherosclerosis susceptibility loci in the mouse model was suggested using recombinant inbred strains of mice. [23] [24] [25] [26] Recently, the chromosomal locations of such loci have been mapped using linkage analysis of experimental crosses. [27] [28] [29] [30] [31] We previously reported the localization of atherosclerosis susceptibility QTL 1 (Athsq1) to chr 4 using a cross between strains MOLF/Ei and C57BL/6J-Ldlr Ϫ/Ϫ . 28 The effect of Athsq1 was independent of systemic risk factors, suggesting a local effect within the vessel wall. We now report confirmation of Athsq1 in congenic strains carrying a 51-megabase (Mb) interval (648 genes). Lesions derived from the congenic mice exhibited prominent accumulation of versican, a major extracellular matrix (ECM) proteoglycan component of human lesions not previously observed in mouse lesions. We also show that both the accelerated atherogenesis and versican accumulation are mediated, at least in part, by bone marrow (BM)-derived cells.
Methods
An expanded Methods section is available in the Supplemental Data (available online at http://atvb.ahajournals.org).
Mice
MOLF/Ei (MOLF) and B6.129S7-Ldlr tm1Her (B6-Ldlr Ϫ/Ϫ ) mice were purchased from The Jackson Laboratory (Bar Harbor, Me). B6.MOLF-Athsq1 congenic mice were generated by introgression of the MOLF donor interval into the B6-Ldlr Ϫ/Ϫ background using a marker-assisted method. 32 Mice designated m*/m* represent a subcongenic strain derived from the m/m strain. Mice (males and females) were fed Western-type diet (WTD) for 12-or 6-weeks before sacrifice as indicated. All procedures were in accordance with institutional guidelines.
DNA Extraction and Ldlr Genotyping
DNA was extracted from tail tips and microsatellite markers and Ldlr alleles were typed by polymerase chain reaction (PCR) as previously described. 28
Atherosclerotic Lesion Measurements
Serial sections were prepared from the aortic root as described. 28, 33 Lesion area was quantified by video microscopy and average lesion size determined from 5 sections per mouse. Necrotic core area was determined from H&E-stained sections as the acellular area beneath the fibrous cap. Cap thickness was determined from Verhoeffstained sections using a scoring system based on numbers of elastic layers as described. 34 Collagen was detected with Masson's trichrome stain (Poly Scientific).
Immunohistochemistry
Versican was detected in aortic sections using a rabbit polyclonal antibody against the ␤-gag domain (Chemicon International).
Protein and mRNA Quantification of Versican
Proximal aortas were collected from 6-week WTD-fed mice. Proteoglycans were extracted, isolated by chromatography, and digested with chondroitin ABC lyase as described. 35 Immunoblots were probed with mouse ␤-gag antibody. Relative abundance of versican was determined by quantitative image analysis. 36 cDNA synthesis from total RNA was carried out using standard procedures. Realtime PCR was performed using Taqman Gene Expression Assays Mm_00490179_ml (mouse versican) and Hs_99999901_sl (18s) for normalization.
BM Transplantation
BM transplantation was performed as described. 33 Irradiated B6-Ldlr Ϫ/Ϫ mice (all females) were injected with BM derived from either m*/m* congenic or b/b noncongenic mice. Reconstitution of the BM with donor cells was checked at 6 weeks postinjection using microsatellite marker D4Mit185. Mice were then fed WTD for 11 weeks, euthanized, and the aortic roots dissected and sectioned as above.
Statistical Analysis
ANOVA and t tests were performed with or without square root transformation, as indicated, using STATVIEW 5.0 (Abacus Concepts Inc). Data are meanϮSD.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results

B6.MOLF-Athsq1 Congenic Mice Exhibit Accelerated Lesion Development
To confirm the Athsq1 susceptibility locus and test its amenability to fine mapping, we created congenic mice carrying one or two copies of the MOLF-derived susceptibility allele from chr 4 on a B6-Ldlr Ϫ/Ϫ background. The full congenic interval extended from D4Mit185 (43 cM) to D4Mit42 (81 cM) ( Figure 1A ). However, homozygous mice carrying the full interval exhibited a high rate of mortality shortly after weaning. The cause of death was unlikely attributable to atherosclerotic complications because the mice died before the start of WTD feeding and, thus, before the onset of atherosclerotic disease. Subcongenic mice carrying a shorter interval, extending from D4Mit185 (43 cM) to D4Mit70 (62 cM) ( Figure 1A ), developed normally in the homozygous state. After 12 weeks of WTD feeding, mean atherosclerotic lesion area was significantly greater in Athsq1 heterozygotes (b/m) and Athsq1 homozygotes carrying the full interval (m/m) or the subcongenic interval (m*/m*) compared to noncongenic littermates (b/b) ( Figure 1B ). The differences in lesion area were independent of plasma cholesterol levels, glucose, body weight, or sex (supplemental Table I and supplemental Figure I ). Homozygous mice were maintained as m*/m* (carrying the shorter interval) for the remaining experiments.
Although the congenic strains exhibited greater lesion area compared to noncongenics after 12-week WTD feeding, lesion development was extensive in all groups. We then examined lesions at an earlier time point and found the effect of Athsq1 to be more dramatic. Figure 1B ).
Analysis of lesion composition revealed dramatic differences between congenic and noncongenic mice at the 6-week time point. While noncongenic littermates exhibited small, focal, fatty streak lesions (Figure 2A , 2D, 2G, and 2J), Athsq1 b/m heterozygotes developed both fatty streak lesions and more advanced fatty-fibrous lesions characterized by fibrous cap and necrotic core formation ( Figure 2B , 2E, 2H, and 2K). In stark contrast to Athsq1 b/b controls, Athsq1 m*/m* homozygotes exhibited advanced fibrous lesions, often covering the entire circumference of the vessel wall ( Figure 2C , 2F, 2I, and 2L). The most advanced lesions from control mice exhibited thin (single elastic layer) fibrous caps, whereas advanced lesions from b/m and m*/m* congenic mice exhibited intermediate (two to four elastic layers) or thick (greater than four elastic layers) fibrous caps (PϽ0.0002 for homozygotes versus controls). 34 Mean necrotic core area, defined as the acellular area encapsulated by the cellular regions of the cap and shoulders, was significantly greater in congenic mice (10 000Ϯ4000 m 2 /section [b/m] and 32 000Ϯ11 000 m 2 /section [m*/m*]) compared to noncongenic controls (300Ϯ1200 m 2 /section; PϽ0.04 and PϽ0.0006, respectively). Thus, the congenic mice exhibited greatly accelerated atherosclerotic lesion development in a gene dosage-dependent manner.
Atherosclerotic Lesions of Athsq1 Congenic Mice Exhibit Prominent Accumulation of the Proatherogenic Matrix Component, Versican
Atherogenesis is initiated by lipoprotein retention and modification, ECM deposition, and inflammatory cell recruitment. To gain insight into the mechanism of accelerated atherogenesis in Athsq1 congenic mice, we examined ECM composition of atherosclerotic lesions using a variety of special stains and antibodies. Staining for collagen, elastin, and hyaluronan showed no obvious differences in comparable lesions derived from Athsq1 m*/m* congenic and Athsq1 b/b noncongenic mice (data not shown). However, immunostaining for versican revealed dramatic accumulations in lesions derived from congenics but not controls. Whereas versican staining was almost undetectable in nonlesional aorta of both control and congenic mice (3.5 weeks WTD, data not shown), staining was prominent in the medial area beneath plaques and was also observed in cellular regions of the intima (Figure 3A through 3D) . In 6-week WTD-fed mice, the mean versican-positive medial area was more than 10-fold greater in Athsq1 m*/m* mice compared to Athsq1 b/b controls (PϽ0.0001; Figure 3E ). Mean intimal lesion staining covered 21% of the total lesion area in congenics compared to 4% in controls (Pϭ0.0008). Similar results were observed in males and females (supplemental Figure II) and 12-week WTD-fed mice ( Figure 3E) .
To confirm the immunohistochemistry data, we performed biochemical analysis of versican in aortic extracts using an antibody specific for the intact core protein. A 2.5-fold increase in versican protein level was observed in extracts from Athsq1 m*/m* congenics compared to Athsq1 b/b controls after 6-week WTD feeding ( Figure 4A and 4B) . By quantitative PCR, we observed no difference in versican mRNA levels between the strains ( Figure 4C ). Furthermore, we observed no differences in mRNA levels of hyaluronase-1 and -2, CD44, or hyaluronan synthase-1 and -2, but a modest decrease in hyaluronan synthase-3 in the congenics (supplemental Figures III and IV) . These data suggest a posttranscriptional mechanism regulating accumulation of versican.
Accelerated Atherosclerosis and Versican Accumulation in Athsq1 Congenic Mice Is Mediated, at Least in Part, by BM-Derived Cells
Beacuse the effect of Athsq1was more dramatic at the earlier time point, and these lesions are enriched with macrophages (compared to smooth muscle cells by immunostaining) (supplemental Figure V) , we performed a BM transplantation experiment to test the role of macrophages in the congenic model. Lethally-irradiated B6-Ldlr Ϫ/Ϫ recipient mice were injected with donor BM derived from congenic or noncongenic mice (both on the B6-Ldlr Ϫ/Ϫ background). The mice were fed WTD for 11 weeks after recovery/repopulation of the BM-derived cells with donor cells. Lesion area was Figure 5A ). The fold-difference in lesion area between mice receiving congenic or control BM (1.6fold) was similar to that shown in Figure 1B , left panel (1.8-fold) after feeding the WTD for similar time periods (11 or 12 weeks). There was also greater accumulation of versican in mice receiving congenic-derived BM ( Figure 5B and 5C): a 2.5-fold increase in versican-positive medial area ( Figure 5D ) and 6/15 mice were positive for intimal staining (1% to 5% of lesion area) compared to none of the mice receiving control BM. These results suggest that BM-derived cells play an important role in development of the lesion susceptibility phenotype, including versican accumulation in lesions.
Discussion
We have confirmed the atherosclerosis susceptibility QTL, Athsq1 on mouse chr 4, in congenic strains. Homozygous congenic mice have a dramatic phenotype with up to 4.5-fold greater lesion area and prominent accumulation of aortic versican compared to controls. We have shown through BM transplantation that the effect of Athsq1 is mediated, at least in part, by BM-derived cells. The association of versican accumulation with accelerated atherogenesis in this model provides in vivo evidence supporting a pathogenic role for versican.
Versican has been indirectly implicated in the pathogenesis of vascular diseases. 39 In atherosclerosis, versican is prominent in the ECM of early intimal thickenings as well as advanced lesions. It is also prominent in restenotic lesions after angioplasty. 40 Versican binds LDL particles with high affinity, 41 and it has been speculated that accumulation of versican in the vessel wall may promote both extracellular lipoprotein retention and intracellular uptake leading to foam cell formation. 39 Versican also binds hyaluronan, forming expanded viscoelastic matrices required for SMC proliferation and migration in cell culture. 42 Migration of SMCs from the media into the intima occurs early in atherogenesis and promotes lesion progression. Versican-hyaluronan structures also promote monocyte aggregation and adhesion 43, 44 via interaction with cell surface receptors including CD44, 45 and L-and P-selectins. 46 Thus, accumulation of versican may provide a local niche for rapid expansion of atherosclerotic plaques via multiple mechanisms.
Although prominent in human atherosclerotic lesions, versican does not appear to be a major matrix component in commonly-used mouse models of atherosclerosis. 47 Kunjathoor and colleagues reported little to no accumulation of versican in early, intermediate, and advanced lesions of both B6-Ldlr Ϫ/Ϫ and B6-Apoe Ϫ/Ϫ mice. 47 Our study is consistent with this earlier work as lesions derived from noncongenic B6-Ldlr Ϫ/Ϫ mice had little versican accumulation (Figure 3) . Thus, the prominent accumulation of aortic versican observed in Athsq1 congenic strains was surprising and suggests a causative role determining disease susceptibility in this model. Versican accumulation was not seen in prelesional aortas of the congenic strain, indicating that there is a differential response to the atherogenic stimulus in congenics compared to controls. Our findings suggest that the MOLFderived gene(s) underlying Athsq1 acts to posttranscriptionally regulate versican accumulation during lesion development.
The original linkage peak for Athsq1 (between D4Mit54 at 66 cM and D4Mit127 at 77 cM) was distal to the introgressed region carried by the m*/m* congenic mice. However, the m*/m* interval overlaps the 2-LOD-unit confidence interval for the QTL (57 to 97 cM) ( Figure 1A) . It is possible that the original QTL was detected because of atherogenic effects of more than one gene. However, the atherosclerotic phenotype of the full m/m congenics was similar to that of the shorter m*/m* congenics ( Figure 1B ), suggesting that the main gene(s) is located within the m*/m* interval.
The congenic interval is large (648 genes) and any discussion about possible candidate genes is highly speculative. However, it is interesting to note that comparative mapping of mouse and human chromosomes revealed that the m*/m* congenic interval contains the homologous region to the human CHD locus on 9p21 ( Figure 6 ). The human locus has been mapped to an interval between CDKN2A and DMRTA1; mouse homologues of these genes reside on chr 4 at 88.9 Mb (Cdkn2a, as taken from NCBI m37 mouse assembly; April 2007) and 89.3 Mb (Dmrta1). Further studies, including fine-mapping of the congenic interval, are required to identify the gene(s) underlying the Athsq1 locus. However, this study illustrates the potential usefulness of the mouse genetics approach when used in conjunction with detailed lesion analysis to define the underlying pathophysiology. 
